Cygnus Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 09-07-2024
- Paid Up Capital ₹ 1.23 Cr
as on 09-07-2024
- Company Age 27 Year, 10 Months
- Last Filing with ROC 31 Mar 2018
- Open Charges ₹ 3.22 Cr
as on 09-07-2024
- Satisfied Charges ₹ 11.59 Cr
as on 09-07-2024
- Revenue -36.28%
(FY 2018)
- Profit -33.02%
(FY 2018)
- Ebitda 0.36%
(FY 2018)
- Net Worth 5.32%
(FY 2018)
- Total Assets -6.71%
(FY 2018)
About Cygnus Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.23 Cr.
The company currently has active open charges totaling ₹3.22 Cr. The company has closed loans amounting to ₹11.59 Cr, as per Ministry of Corporate Affairs (MCA) records.
Chetan Gandhi and Chaula Gandhi serve as directors at the Company.
- CIN/LLPIN
U24231WB1997PTC082943
- Company No.
082943
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Feb 1997
- Date of AGM
29 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Cygnus Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chetan Gandhi  | Director | 17-Feb-1997 | Current |
| Chaula Gandhi | Director | 10-Aug-2005 | Current |
Financial Performance of Cygnus Pharmaceuticals.
Cygnus Pharmaceuticals Private Limited, for the financial year ended 2018, experienced significant reduction in revenue, with a 36.28% decrease. The company also saw a substantial fall in profitability, with a 33.02% decrease in profit. The company's net worth moved up by a moderate rise of 5.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cygnus Pharmaceuticals?
In 2018, Cygnus Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Aug 2018 | ₹1.15 M | Open |
Axis Bank Limited Creation Date: 23 Jul 2018 | ₹3.10 Cr | Open |
Idbi Bank Limited Creation Date: 30 Mar 2015 | ₹5.00 Cr | Satisfied |
How Many Employees Work at Cygnus Pharmaceuticals?
Cygnus Pharmaceuticals has a workforce of 1 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cygnus Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cygnus Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
